| Name | Title | Contact Details |
|---|---|---|
Jackie McGuckin |
VP of Talent Acquisition | Profile |
Megean Steinberger |
Clinical Talent Director | Profile |
Abbie Salyzyn |
Human Resources Director | Profile |
Heidi Faust |
Chief People Officer | Profile |
Emily Simonian |
Head of Learning | Profile |
Fast Lane Mobile Advertising is a Dunkirk, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Innovation Place is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
The Private Diagnostic Clinic (PDC) is the physician practice of Duke Health. It is one of the first and the largest academic multi-specialty group practices in the United States. The PDC is a member-led organization more than 1,600 members, and is governed by a Board of Managers. As a professional limited liability company (PLLC), the PDC owns and operates primary care and specialty care clinics in central and eastern North Carolina, as well as the Triad. Through a diverse and integrated network of providers, patients have convenient, accessible and high quality primary and specialty care close to home. In addition to patient care, PDC members conduct cutting-edge research and train the future health care workforce as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke`s clinical, research and academic missions.
Baker Dental Corp is a Hawthorn Woods, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.